Other hold-ups are:
Only 30 out of the 50 countries targeted have established treatment goals.
Of the estimated 4 million people in Africa who need anti-retrovirals, only 325,000 (8%) were on treatment by December.
Despite huge successes in Uganda and Botswana, for example, with both countries already delivering anti-retrovirals to half their affected populations, the burden of disease remains great and the distribution of anti-retrovirals is poor in South Africa, Nigeria, Zimbabwe, Tanzania and Ethiopia.
The Lancet comments that if the programme “had the political clout to influence South Africa alone to implement all its recommendations, where the necessary infrastructure largely exists, then the 3 million target would be more likely to be attained. Without South Africa on board, with its 837 000 people affected by HIV/AIDS and its leadership position within Africa, 3 by 5 is but a pipe dream.”